Stéphane Mouret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stéphane Mouret has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Julie Charles
CHU de Grenoble, 38700 Grenoble, France
3 shared publications - Aude Belbezier
Department of Dermatology, Allergology and Photobiology Grenoble University Hospital Grenoble France
2 shared publications Abdallah Ghaith
Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2 , Grenoble
1 shared publication- Alain Dupuy
Department of Dermatology Univ Rennes, CHU Rennes Rennes France
1 shared publication - Amandine Hurbin
Institute for Advanced Biosciences, Institut National de la Santé Et de la Recherche Médicale INSERM U1209, Centre National de la Recherche Scientifique CNRS UMR5309, Université Grenoble Alpes, F-38000 Grenoble, France
1 shared publication Andreea Stefan
French Network of Rare Skin Cancers, CARADERM, France
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72295
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study
Background: Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer. Somatostatin analogues, such as lanreotide, have shown efficacy in managing other neuroendocrine tumors. Retrospective studies suggest that lanreotide may induce partial response or disease stabilization in patients with advanced MCC. To test this hypothesis, we conducted a Phase II, non‐randomized, open trial investigating lanreotide in MCC patients with advanced disease ( ClinicalTrials.gov identifier: NCT02351128). Methods: Patients with Stage IIIB‐IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity. The primary endpoint was disease control rate (DCR) (defined as the proportion of patients with complete response, partial response, and stable disease) at 3 months. Secondary endpoints included progression‐free survival (PFS), overall survival (OS), somatostatin receptor (SSTR) tumor expression, and treatment safety. Results: Between April, 2015, and November, 2016, 35 patients received lanreotide, with 12 evaluable at 3 months. The DCR at 3 months was 33.3% (4) among evaluable patients (all with stable disease) and 11.4% for the full cohort. Statistical analyses showed no significant difference from the expected 20% response rate ( p = 0.205 for intention‐to‐treat; p = 0.939 for per‐protocol). Kaplan–Meier analysis revealed median OS and PFS of 3.1 months (95% CI, 2–5.5) and 3.5 months (95% CI, 2.3–5.5), respectively. SSTR tumor expression did not correlate with treatment response. Conclusion: Although limited by its implementation before the era of immunotherapy, this non‐randomized study shows the limited effectiveness of lanreotide as monotherapy in treating patients with advanced MCC. Trial Registration: Identifier: NCT02351128
- 25 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72295
Open AccessLanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study
Background: Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer. Somatostatin analogues, such as lanreotide, have shown efficacy in managing other neuroendocrine tumors. Retrospective studies suggest that lanreotide may induce partial response or disease stabilization in patients with advanced MCC. To test this hypothesis, we conducted a Phase II, non‐randomized, open trial investigating lanreotide in MCC patients with advanced disease ( ClinicalTrials.gov identifier: NCT02351128). Methods: Patients with Stage IIIB‐IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity. The primary endpoint was disease control rate (DCR) (defined as the proportion of patients with complete response, partial response, and stable disease) at 3 months. Secondary endpoints included progression‐free survival (PFS), overall survival (OS), somatostatin receptor (SSTR) tumor expression, and treatment safety. Results: Between April, 2015, and November, 2016, 35 patients received lanreotide, with 12 evaluable at 3 months. The DCR at 3 months was 33.3% (4) among evaluable patients (all with stable disease) and 11.4% for the full cohort. Statistical analyses showed no significant difference from the expected 20% response rate ( p = 0.205 for intention‐to‐treat; p = 0.939 for per‐protocol). Kaplan–Meier analysis revealed median OS and PFS of 3.1 months (95% CI, 2–5.5) and 3.5 months (95% CI, 2.3–5.5), respectively. SSTR tumor expression did not correlate with treatment response. Conclusion: Although limited by its implementation before the era of immunotherapy, this non‐randomized study shows the limited effectiveness of lanreotide as monotherapy in treating patients with advanced MCC. Trial Registration: Identifier: NCT02351128
- Open Access
- 4 August 2026
- Published by Wiley in Immunology
- Vol. 179 (3) , 486-515
Metabolic Profiling of Circulating and Tumour‐Infiltrating T Cells Uncovers Bioenergetic Checkpoints Linked With Immune and Clinical Skewing in Melanoma Patients
Metabolism is critical for immune cell functions. Tumours shape their microenvironment to render it metabolically hostile for infiltrating immune cells. While targeting immunometabolism emerges as a promising way to reinvigorate anticancer immunity, a deeper understanding of the metabolic disturbances of immune cells is needed. Here, we explored how the metabolic status of T cells governs immune skewing from circulating and tumour‐infiltrating CD4 + and CD8 + T cells of melanoma patients at a single‐cell level using the SCENITH method and targeted metabolomics. Circulating and tumour‐infiltrating T cells from patients displayed a decreased mitochondrial dependency associated with an enhanced glycolytic capacity and a skewed metabolic reprogramming upon stimulation. Such metabolic disturbances were linked to the activation status, immune checkpoint profile and functional orientation of T cells, underlining critical connections between T‐cell features and metabolic patterns. Targeted metabolomics within sorted CD4 + /CD8 + T cells identified a decrease in citrulline, cysteine and threonine within all subsets in patients, together with a sharp rise in sterol cholesterol CE(20:2) and ceramide dhCer(d18:0/22:0) within tumour‐infiltrating CD4 + T cells, and in glycerolipid DG(16:0/16:0) within CD8 + T cells in blood and tumour. We further outlined a metabolic‐checkpoint‐based signature composed of six genes coding enzymes/transporters connected to the imbalanced metabolites found within tumour‐infiltrating T cells ( LIPA , DGKA , GLUL , SLC38A1 , SLC7A7 , GCH1 ) that shape patients' clinical outcome. These findings outline the skewed bioenergetic profiles of T cells and depict metabolic checkpoints associated with immune subversion. Harnessing metabolic pathways is promising for developing innovative therapies to restore optimal anti‐tumour responses and improve clinical success.
- 4 August 2026
- Published by Wiley in Immunology
- Vol. 179 (3) , 486-515
Open AccessMetabolic Profiling of Circulating and Tumour‐Infiltrating T Cells Uncovers Bioenergetic Checkpoints Linked With Immune and Clinical Skewing in Melanoma Patients
Metabolism is critical for immune cell functions. Tumours shape their microenvironment to render it metabolically hostile for infiltrating immune cells. While targeting immunometabolism emerges as a promising way to reinvigorate anticancer immunity, a deeper understanding of the metabolic disturbances of immune cells is needed. Here, we explored how the metabolic status of T cells governs immune skewing from circulating and tumour‐infiltrating CD4 + and CD8 + T cells of melanoma patients at a single‐cell level using the SCENITH method and targeted metabolomics. Circulating and tumour‐infiltrating T cells from patients displayed a decreased mitochondrial dependency associated with an enhanced glycolytic capacity and a skewed metabolic reprogramming upon stimulation. Such metabolic disturbances were linked to the activation status, immune checkpoint profile and functional orientation of T cells, underlining critical connections between T‐cell features and metabolic patterns. Targeted metabolomics within sorted CD4 + /CD8 + T cells identified a decrease in citrulline, cysteine and threonine within all subsets in patients, together with a sharp rise in sterol cholesterol CE(20:2) and ceramide dhCer(d18:0/22:0) within tumour‐infiltrating CD4 + T cells, and in glycerolipid DG(16:0/16:0) within CD8 + T cells in blood and tumour. We further outlined a metabolic‐checkpoint‐based signature composed of six genes coding enzymes/transporters connected to the imbalanced metabolites found within tumour‐infiltrating T cells ( LIPA , DGKA , GLUL , SLC38A1 , SLC7A7 , GCH1 ) that shape patients' clinical outcome. These findings outline the skewed bioenergetic profiles of T cells and depict metabolic checkpoints associated with immune subversion. Harnessing metabolic pathways is promising for developing innovative therapies to restore optimal anti‐tumour responses and improve clinical success.
- 3 August 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (8)
Improvement of frailty and prefrailty in older cancer survivors: a 6-month home-based pilot study
Background: Frailty affects 42% of older patients with cancer and is a predictor of cancer recurrence and mortality. Its impact on older cancer survivors has not yet been extensively studied. Objective: Assess the impact of a multicomponent home-based intervention on frailty prevalence in older adults in remission from cancer. Design: Bicentric before-and-after non-randomised intervention study (NCT04746768). Setting: Community-dwelling. Subjects: Patients ≥70 years old in remission from cancer who met at least one criterion for the Fried phenotype. Methods: A 6-month multicomponent home-based intervention was performed combining supervised exercise training and personalised nutritional support. The primary endpoint was the proportion of patients who achieved frailty or prefrailty improvement from the initial assessment (M0) to M6. Results: The mean age of the 110 participants was 77 (SD = 5) years. At baseline, 45% were frail and none were robust. Eighty-one completed the intervention (Completion Group: CG). In CG, functional, physical performance measures and the T-stage of cancer were associated with baseline frailty, while none of the other cancer-related characteristics were. Among the CG, 62% improved their frailty status at M6: 78% of frails improved, 51% of pre-frail became robust. Frailty severity decreased at M6 in 74% of participants. Vitamin D showed a group × time interaction, suggesting that frailty trajectories differed according to vitamin D status. Conclusions: These preliminary findings suggest a potential beneficial effect of a home-based multicomponent intervention to improve frailty in community-dwelling older cancer survivors. Further controlled and adequately powered trials are required to confirm these findings.
- 3 August 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (8)
Improvement of frailty and prefrailty in older cancer survivors: a 6-month home-based pilot study
Background: Frailty affects 42% of older patients with cancer and is a predictor of cancer recurrence and mortality. Its impact on older cancer survivors has not yet been extensively studied. Objective: Assess the impact of a multicomponent home-based intervention on frailty prevalence in older adults in remission from cancer. Design: Bicentric before-and-after non-randomised intervention study (NCT04746768). Setting: Community-dwelling. Subjects: Patients ≥70 years old in remission from cancer who met at least one criterion for the Fried phenotype. Methods: A 6-month multicomponent home-based intervention was performed combining supervised exercise training and personalised nutritional support. The primary endpoint was the proportion of patients who achieved frailty or prefrailty improvement from the initial assessment (M0) to M6. Results: The mean age of the 110 participants was 77 (SD = 5) years. At baseline, 45% were frail and none were robust. Eighty-one completed the intervention (Completion Group: CG). In CG, functional, physical performance measures and the T-stage of cancer were associated with baseline frailty, while none of the other cancer-related characteristics were. Among the CG, 62% improved their frailty status at M6: 78% of frails improved, 51% of pre-frail became robust. Frailty severity decreased at M6 in 74% of participants. Vitamin D showed a group × time interaction, suggesting that frailty trajectories differed according to vitamin D status. Conclusions: These preliminary findings suggest a potential beneficial effect of a home-based multicomponent intervention to improve frailty in community-dwelling older cancer survivors. Further controlled and adequately powered trials are required to confirm these findings.
- 27 August 2025
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 152 (3) , 103416
Acquired cutaneous pseudoxanthoma elasticum progressing after chronic liver transplant rejection
- 27 August 2025
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 152 (3) , 103416
Acquired cutaneous pseudoxanthoma elasticum progressing after chronic liver transplant rejection
- 12 August 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 422-426.e8
Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma
- 12 August 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 422-426.e8
Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma
- 19 November 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A122-A123
Immunothérapie dans le mélanome en hospitalisation à domicile : enquête de satisfaction et retour d’expérience des centres français d’oncodermatologie
- 19 November 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A122-A123
Immunothérapie dans le mélanome en hospitalisation à domicile : enquête de satisfaction et retour d’expérience des centres français d’oncodermatologie